Management of Mycobacterium Abscessus Infections: The Rise of a Superbug

<p>Infections caused by Mycobacterium abscessus appear to be increasing in frequency among the immunocompromised population and are challenging to treat. Antibiotic options in these cases are scarce, prologued therapy is required and new options are needed. We will discuss this important topic with experts in the field.</p> <h2><strong>Topics discussed:</strong></h2> <ul> <li>Define M. abscessus as an opportunistic pathoge</li> <li>The intrinsic phenotypic characteristics of M. abscessus, including resistance to common antimicrobials</li> <li>Treatment approaches and rationale for these strategies</li> </ul> <h2><strong>Guests:</strong></h2> <ul> <li>Kelly Dooley, MD. PhD, MPH.  Professor of Medicine, Johns Hopkins University and Editor of AAC</li> <li>Charles L. Daley, MD, Professor and Chief of the Division of Mycobacterial and Respiratory Infections. National Jewish Health</li> <li>Thomas Dick, PhD. Professor, Center for Discovery and Innovation, Hackensack Meridian Health</li> </ul> <p>This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at <a href="https://aac.asm.org" target="_blank" rel="noopener">aac.asm.org</a>. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit <a href="https://asm.org/membership" target="_blank" rel= "noopener">asm.org/membership</a> to sign up</p> <p dir="ltr">Visit <a href="https://journals.asm.org/journal/aac" target="_blank" rel="noopener">journals.asm.org/journal/aac</a> to browse issues and/or submit a manuscript.</p>